KR20200035496A - 치료학적 단백질 제형의 제조 방법 및 이러한 방법에 의해 생산된 항체 제형 - Google Patents

치료학적 단백질 제형의 제조 방법 및 이러한 방법에 의해 생산된 항체 제형 Download PDF

Info

Publication number
KR20200035496A
KR20200035496A KR1020207008879A KR20207008879A KR20200035496A KR 20200035496 A KR20200035496 A KR 20200035496A KR 1020207008879 A KR1020207008879 A KR 1020207008879A KR 20207008879 A KR20207008879 A KR 20207008879A KR 20200035496 A KR20200035496 A KR 20200035496A
Authority
KR
South Korea
Prior art keywords
concentration
excipient
protein
ser
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207008879A
Other languages
English (en)
Korean (ko)
Inventor
쥬디 케이 글린
브라이언 신 첸
다니엘 패트릭 라카시
Original Assignee
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 화이자 인코포레이티드 filed Critical 화이자 인코포레이티드
Publication of KR20200035496A publication Critical patent/KR20200035496A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Water Supply & Treatment (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020207008879A 2015-09-22 2016-09-08 치료학적 단백질 제형의 제조 방법 및 이러한 방법에 의해 생산된 항체 제형 Ceased KR20200035496A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562222067P 2015-09-22 2015-09-22
US62/222,067 2015-09-22
PCT/IB2016/055355 WO2017051273A1 (en) 2015-09-22 2016-09-08 Method of preparing a therapeutic protein formulation and antibody formulation produced by such a method

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187007855A Division KR20180037056A (ko) 2015-09-22 2016-09-08 치료학적 단백질 제형의 제조 방법 및 이러한 방법에 의해 생산된 항체 제형

Publications (1)

Publication Number Publication Date
KR20200035496A true KR20200035496A (ko) 2020-04-03

Family

ID=57045234

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207008879A Ceased KR20200035496A (ko) 2015-09-22 2016-09-08 치료학적 단백질 제형의 제조 방법 및 이러한 방법에 의해 생산된 항체 제형
KR1020187007855A Ceased KR20180037056A (ko) 2015-09-22 2016-09-08 치료학적 단백질 제형의 제조 방법 및 이러한 방법에 의해 생산된 항체 제형

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187007855A Ceased KR20180037056A (ko) 2015-09-22 2016-09-08 치료학적 단백질 제형의 제조 방법 및 이러한 방법에 의해 생산된 항체 제형

Country Status (11)

Country Link
US (1) US20230134160A1 (enExample)
EP (1) EP3352790A1 (enExample)
JP (1) JP6925111B2 (enExample)
KR (2) KR20200035496A (enExample)
CN (1) CN108025072A (enExample)
AU (1) AU2016329034B2 (enExample)
CA (1) CA2999118C (enExample)
HK (1) HK1255006A1 (enExample)
IL (1) IL258311B (enExample)
MX (1) MX2018003298A (enExample)
WO (1) WO2017051273A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019517473A (ja) 2016-05-27 2019-06-24 アレクシオン ファーマシューティカルズ インコーポレイテッドＡｌｅｘｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 難治性全身型重症筋無力症の処置のための方法
KR20200070355A (ko) 2017-10-26 2020-06-17 알렉시온 파마슈티칼스, 인코포레이티드 발작성 야간 혈색소뇨 (pnh) 및 비정형 용혈성 요독 증후군 (ahus)의 치료를 위한 항-c5 항체의 투여량 및 투여
CN112088013B (zh) * 2018-03-26 2024-12-06 勃林格殷格翰动物保健美国有限公司 制备免疫原性组合物的方法
NZ770284A (en) 2018-05-10 2025-11-28 Regeneron Pharma High concentration vegf receptor fusion protein containing formulations
WO2020006266A1 (en) * 2018-06-28 2020-01-02 Alexion Pharmaceuticals, Inc. Methods of producing anti-c5 antibodies
EP3837273B1 (en) * 2018-08-14 2025-09-24 Bristol-Myers Squibb Company Improved protein recovery
CN111110841A (zh) * 2018-10-31 2020-05-08 上海君实生物医药科技股份有限公司 含有抗pcsk9抗体的稳定制剂
EP3782666B1 (en) 2019-01-24 2021-08-11 Magenta Medical Ltd. Manufacturing an impeller
TWI871300B (zh) * 2019-01-28 2025-02-01 美商安進公司 藉由將藥物物質和藥物產品過程整體化的生物製劑製造之連續製造過程
MX2021009851A (es) 2019-02-18 2021-09-10 Lilly Co Eli Formulacion de anticuerpos terapeuticos.
WO2021171310A1 (en) * 2020-02-24 2021-09-02 Indian Institute Of Technology Delhi A system for real-time monitoring of protein and excipients
CN111944046B (zh) * 2020-08-28 2021-04-09 江苏荃信生物医药有限公司 高浓度、低粘度抗人il-23单克隆抗体溶液的制备方法
WO2022041390A1 (zh) * 2020-08-28 2022-03-03 江苏荃信生物医药股份有限公司 包含高浓度抗人白介素23单克隆抗体的低粘度液体制剂及其制备方法
KR20230127292A (ko) * 2020-12-30 2023-08-31 아이-맵 바이오파마 컴파니 리미티드 항-cd73 항체의 제제
CN114014929B (zh) * 2021-11-04 2022-07-19 江苏荃信生物医药股份有限公司 一种抗人白介素-33单克隆抗体浓缩溶液的制备方法
JP2025530825A (ja) 2022-09-14 2025-09-17 マジェンタ・メディカル・リミテッド 心室補助デバイスの湾曲
WO2024165043A1 (en) * 2023-02-08 2024-08-15 Beigene Switzerland Gmbh Preparation methods for a highly concentrated pd1 antibody solution by applying single-pass tangential flow filtration (sptff)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9415102B2 (en) * 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
US20060051347A1 (en) * 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
DK1865986T3 (en) * 2005-03-08 2016-04-11 Pfizer Prod Inc The anti-CTLA-4 antibody compositions
CN101553504A (zh) * 2006-12-11 2009-10-07 豪夫迈·罗氏有限公司 Aβ抗体胃肠外制剂
US20090208492A1 (en) * 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
WO2010042705A1 (en) * 2008-10-09 2010-04-15 Medimmune, Llc Antibody formulation
US8298535B2 (en) * 2010-02-24 2012-10-30 Rinat Neuroscience Corp. Anti-IL-7 receptor antibodies
EA022220B1 (ru) * 2010-02-24 2015-11-30 Сюменекс А/С Способ получения и очистки рекомбинантной лизосомальной альфа-маннозидазы
WO2012168491A1 (en) * 2011-06-10 2012-12-13 Novartis Ag Pharmaceutical formulations of pcsk9 antagonists
EP2583980A1 (en) * 2011-10-19 2013-04-24 Effimune Antibodies directed against the alpha chain of IL7 receptor - their use for the preparation of drug candidates
BR112014028129A2 (pt) * 2012-05-14 2017-06-27 Novo Nordisk As soluções de proteína estabilizadas
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
EP2727602A1 (en) * 2012-10-31 2014-05-07 Takeda GmbH Method for preparation of a high concentration liquid formulation of an antibody

Also Published As

Publication number Publication date
WO2017051273A1 (en) 2017-03-30
EP3352790A1 (en) 2018-08-01
US20230134160A1 (en) 2023-05-04
IL258311A (en) 2018-05-31
JP2017095440A (ja) 2017-06-01
AU2016329034B2 (en) 2019-05-23
CA2999118A1 (en) 2017-03-30
JP6925111B2 (ja) 2021-08-25
IL258311B (en) 2021-04-29
KR20180037056A (ko) 2018-04-10
HK1255006A1 (zh) 2019-08-02
RU2018110145A3 (enExample) 2020-02-10
CN108025072A (zh) 2018-05-11
AU2016329034A1 (en) 2018-03-15
MX2018003298A (es) 2018-06-20
RU2018110145A (ru) 2019-10-23
CA2999118C (en) 2022-06-14

Similar Documents

Publication Publication Date Title
KR20200035496A (ko) 치료학적 단백질 제형의 제조 방법 및 이러한 방법에 의해 생산된 항체 제형
US20200255496A1 (en) Vegfr-fc fusion protein formulations
JP2012511531A (ja) 賦形剤不含抗体溶液を得るための方法
US20160251441A1 (en) Antibody purification
US20230065872A1 (en) Excipient compounds for protein processing
KR20190117631A (ko) 단백질 가공 처리를 위한 부형제 화합물
CN112512561A (zh) 稳定的融合蛋白制剂
US20230279146A1 (en) Viscosity reducing excipients and combinations thereof for highly concentrated protein formulations
JP2021525255A (ja) ＣＴＬＡ４−Ｉｇ融合タンパク質製剤
CN114423414A (zh) 樟脑磺酸及其与阳离子赋形剂的组合作为高浓缩蛋白质制剂中的降粘剂
RU2779389C2 (ru) Способ получения терапевтического белкового препарата и препарат на основе антител, полученный по такому способу
CA3076423A1 (en) Pharmaceutical formulations for adalimumab
JP7733643B2 (ja) タンパク質の精製およびウイルス不活性化
US20240374720A1 (en) Antibody formulations and uses thereof
JP2023506173A (ja) タンパク質のバイオプロセス
WO2025131987A1 (en) Viscosity reducing excipients and combinations thereof for liquid compositions comprising a protein
RU2020142735A (ru) Состав слитого белка ctla4-ig
HK40090241A (zh) 用於高度浓缩蛋白质制剂的粘度降低赋形剂及其组合

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20200327

Application number text: 1020187007855

Filing date: 20180320

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200608

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20210405

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20200608

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20210405

Comment text: Decision to Refuse Application

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20210802

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20210705

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20210405

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20200608

X601 Decision of rejection after re-examination